




IL23A Antibody

Product Code	CSB-RA251959A0HU
Storage	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Uniprot No.	Q9NPF7
Immunogen	A synthesized peptide derived from human IL23
Species Reactivity	Human
Tested Applications	ELISA, WB; Recommended dilution: WB:1:500-1:5000
Relevance	Associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.
Form	Liquid
Conjugate	Non-conjugated
Storage Buffer	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Purification Method	Affinity-chromatography
Isotype	Rabbit IgG
Clonality	Monoclonal
Product Type	Recombinant Antibody
Immunogen Species	Homo sapiens (Human)
Research Area	Cancer; Immunology
Gene Names	IL23A
Accession NO.	1F6

Image



Western Blot

Positive WB detected in: THP-1 whole cell lysate

All lanes: IL23 antibody at 1:1000

Secondary

Goat polyclonal to rabbit IgG at 1/50000 dilution

Predicted band size: 21 kDa

Observed band size: 21 kDa



Description

IL23A encodes the p19 helical-bundle subunit (IL-23p19), which is a disulfide linked to a p40 subunit (IL-12p40) to make up the heterodimeric cytokine IL23. et al showed that IL-23p19 can suppress tumor metastases and initiation controlled by NK cell-mediated immunity. In particular, NK cell perforin and IFN- γ effector functions appear to be suppressed by host IL-23p19, and suppression is independent of host IL-17A. The revelation that IL-2 therapy was superior in IL-23p19-deficient hosts, and independent of IL-17, suggests clearly that anti-human IL-23p19 mAbs may be of great value in improving the current clinical use of IL-2 in a variety of human cancer patients.

The generation of this recombinant IL23A antibody occurs in a series of steps: immunization, splenocytes & PBMC, single B cell sorting, mRNA extraction, RT-PCR & insert vector, expression, ELISA validation. And ELISA, WB was carried out Every step was performed under strict standards to ensure the researchers can have a recombinant IL23A antibody with premium quality.